Androgen receptor variant 7 (AR-V7) in sequencing therapeutic agents for castratrion resistant prostate cancer: A critical review
01 Pubblicazione su rivista
Sciarra Alessandro, Gentilucci Alessandro, Silvestri Ida, Salciccia Stefano, Cattarino Susanna, Scarpa Susanna, Gatto Antonio, Frantellizzi Viviana, Von Heland Magnus, Ricciuti Gian Piero, Del Giudice Francesco, Maggi Martina
ISSN: 0025-7974
androgen receptor variant 7 (AR-V7) has been suggested as potential marker for treatment selection in men with metastatic castration-resistant prostate cancer (mCRPC). The aim of the present review is to critically analyze: frequency of the AR-V7 expression in mCRPC cases-impact of AR-V7 expression on abiraterone, enzalutamide, and taxane therapy.